BPC-157: Preclinical Tissue-Repair Profile
internal_protocolpreclinical · status: needs_provider_reviewDetails
Author: Axiom Knowledge Base
Citation: Internal reference summary compiled for the Axiom knowledge base (2026).
File: signed link
Summary (generated — provider review required)
BPC-157 is a synthetic pentadecapeptide derived from a sequence identified in human gastric juice. The evidence base is predominantly preclinical (rodent models), with limited controlled human data. Mechanism.
The original source document remains the source of truth. Generated summaries are not authoritative.
Linked assets (4) · phenotypes (0)
evidence_reference, mechanism, safety_reference, dosing_reference
Findings (5) · awaiting review (3)
mechanism · pending
Mechanism.
mechanism · pending
Reported effects in animal studies include promotion of angiogenesis, modulation of growth factor pathways (including VEGF signaling), upregulation of the nitric oxide system, and effects on fibroblast migration.
safety · pending
Safety and regulatory considerations.
safety · pending
Human safety data are limited and the regulatory status varies by jurisdiction; it is not an approved drug in many regions.
dosing · pending
This summary organizes mechanistic and preclinical background for provider review and does not constitute a treatment recommendation or dosing guidance.
Processing
Processed into 1 searchable section.